Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
NCT02387216 · Elevation Oncology · PHASE2 · terminated · last registry update 2021-10-12 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on the preliminary results seen during interim analysis, which were confirmed in the final analysis, the Sponsor terminated the study” | Open Targets' class: negative | Registry record, Elevation Oncology |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB3 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-18Phase 3 first posted: Spectrum Pharmaceuticals, Inc, Poziotinib + Docetaxel (NCT05378763)
- 2022-04-21Phase 3 first posted: Daiichi Sankyo, Patritumab Deruxtecan + Platinum-based chemotherapy (NCT05338970)
- 2021-10-07Results posted on the registry: Cancer Research UK, Vandetanib, Selumetinib + Vandetanib, Selumetinib (NCT01586624)
- 2021-06-16Results posted on the registry: Daiichi Sankyo, U3-1287 + Erlotinib (NCT01211483)
- 2020-11-17Also stopped (terminated): Hanmi Pharmaceutical Company Limited, Poziotinib (NCT04044170)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision